Table: Taisho Pharmaceutical HD - 6-MTH group results
Oct 29 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2020 Sep 30, 2019 Mar 31, 2021
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 145.90 132.21 289.50
(+10.4 pct) (+2.1 pct) (+0.3 pct)
Operating 16.30 14.53 20.00
(+12.2 pct) (-14.5 pct) (-5.4 pct)
Recurring 18.86 14.61 23.00
(+29.1 pct) (-35.7 pct) (-6.0 pct)
Net 11.29 14.78 13.00
(-23.6 pct) (-65.2 pct) (-35.6 pct)
EPS 141.51 yen 185.23 yen 162.89 yen
EPS Diluted 141.34 yen 185.02 yen
Ann Div 110.00 yen 100.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 60.00 yen 50.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10